

NON-TECHNICAL ABSTRACT

The purpose of this research study is to develop a combined immune based therapy that consists of 1) stem cell transplantation and donor lymphocyte infusion followed by 2) vaccinations with donor-derived dendritic cells mixed with the patient's tumor RNA. In earlier trials these strategies independently have shown safety and signs of therapeutic effects. Here we hypothesize that these two regimens combined will enhance the anti-tumor immune response which will translate into a clinical response and will impact on tumor progression and long-term survival.

The main objectives of this study are:

- 1) To evaluate the safety of administering injections of donor-derived dendritic cells mixed with patient's own tumor RNA after non-myeloablative allogeneic peripheral blood stem cell transplantation (NMSCT) and donor lymphocyte infusion (DLI).
- 2) To estimate immune response.
- 3) To estimate clinical response.